MY170949A - A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine - Google Patents

A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Info

Publication number
MY170949A
MY170949A MYPI2011003259A MYPI2011003259A MY170949A MY 170949 A MY170949 A MY 170949A MY PI2011003259 A MYPI2011003259 A MY PI2011003259A MY PI2011003259 A MYPI2011003259 A MY PI2011003259A MY 170949 A MY170949 A MY 170949A
Authority
MY
Malaysia
Prior art keywords
peptide
cancer vaccine
hla
binding
molecule
Prior art date
Application number
MYPI2011003259A
Other languages
English (en)
Inventor
Sok Ching Cheong
Soo Hwang Teo
Kue Peng Lim
Mohd Zain Rosnah
Ariff Abdul Rahman Zainal
Ponniah Sathibalan
Original Assignee
Cancer Res Initiatives Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Initiatives Foundation filed Critical Cancer Res Initiatives Foundation
Priority to MYPI2011003259A priority Critical patent/MY170949A/en
Priority to PCT/MY2012/000198 priority patent/WO2013009165A1/en
Priority to TW101124710A priority patent/TWI567088B/zh
Publication of MY170949A publication Critical patent/MY170949A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MYPI2011003259A 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine MY170949A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
PCT/MY2012/000198 WO2013009165A1 (en) 2011-07-11 2012-07-05 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
TW101124710A TWI567088B (zh) 2011-07-11 2012-07-10 能結合人類白血球抗原（ｈｌａ）分子的胜肽、由此胜肽衍生出的癌症疫苗及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Publications (1)

Publication Number Publication Date
MY170949A true MY170949A (en) 2019-09-20

Family

ID=47506273

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Country Status (3)

Country Link
MY (1) MY170949A (zh)
TW (1) TWI567088B (zh)
WO (1) WO2013009165A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192920A (en) 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
WO2018225732A1 (ja) * 2017-06-05 2018-12-13 国立大学法人三重大学 Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
EP2334826A4 (en) * 2008-09-12 2012-01-25 Cancer Res Initiative Foundation PROCEDURE FOR THE DETECTION AND DIAGNOSIS OF ORAL AND NASOPHARYNGEAL TUMORS

Also Published As

Publication number Publication date
TW201302801A (zh) 2013-01-16
WO2013009165A1 (en) 2013-01-17
TWI567088B (zh) 2017-01-21

Similar Documents

Publication Publication Date Title
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2020011675A (es) Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
EA201791925A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
MX364777B (es) Péptidos cancerígenos universales derivados de telomerasa.
MX353165B (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
MX2016002937A (es) Vacuna oncologica.
JP2014502961A5 (zh)
NZ594198A (en) Neil3 peptides and vaccines including the same
MX2012008657A (es) Peptidos melk modificados y vacunas que contienen los mismos.
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
MY170949A (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
NZ611361A (en) Tomm34 peptides and vaccines including the same
MX2015009086A (es) Peptido.
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
NZ593086A (en) Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility
MY182584A (en) Helicobacter pylori proteins for diagnostic kit and vaccine
NZ746513A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors